AbbVie Inc. Non-operating Income/Expense

Non-operating Income/Expense of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Non-operating Income/Expense growth rates and interactive chart. Income or expense that is usually non-recurring and not tied to a company's operations. It is stated separately on the income statement to differentiate it from operating expenses.

Highlights and Quick Summary

  • Non-operating Income/Expense for the quarter ending December 30, 2019 was $-882 Million (a 43.18% increase compared to previous quarter)
  • Year-over-year quarterly Non-operating Income/Expense increased by 89.27%
  • Annual Non-operating Income/Expense for 2019 was $-4.56 Billion (a 284.23% increase from previous year)
  • Annual Non-operating Income/Expense for 2018 was $-1.19 Billion (a -34.76% decrease from previous year)
  • Annual Non-operating Income/Expense for 2017 was $-1.82 Billion (a 24.86% increase from previous year)
  • Twelve month Non-operating Income/Expense ending December 30, 2019 was $-4.56 Billion (a 26.34% increase compared to previous quarter)
  • Twelve month trailing Non-operating Income/Expense increased by 194.76% year-over-year
Trailing Non-operating Income/Expense for the last four month:
30 Dec '19 29 Sep '19 29 Jun '19 30 Mar '19
$-4.56 Billion $-3.61 Billion $-3.39 Billion $-1.55 Billion
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Non-operating Income/Expense of AbbVie Inc.

Most recent Non-operating Income/Expenseof ABBV including historical data for past 10 years.

Interactive Chart of Non-operating Income/Expense of AbbVie Inc.

AbbVie Inc. Non-operating Income/Expense for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $-882.0 $-616.0 $-2,593.0 $-466.0 $-4,557.0
2018 $68.0 $-398.0 $-750.0 $-106.0 $-1,186.0
2017 $-589.0 $-599.0 $-309.0 $-321.0 $-1,818.0
2016 $-316.0 $-347.0 $-291.0 $-502.0 $-1,456.0
2015 $-189.0 $-238.0 $-174.0 $-291.0 $-892.0
2014 $-622.0 $-273.0 $-82.0 $-65.0 $-1,042.0
2013 $-96.0 $-85.0 $-85.0 $-66.0 $-332.0
2012 $-108.0 $8.0 $-20.0 $28.0 $-92.0
2011 – – $14.12 $33.89 $48.0
2010 – – – – $119.0
2009 – – – – $1,018.52

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
© stockrow.com